Skip to main content
. Author manuscript; available in PMC: 2022 Aug 3.
Published in final edited form as: Pediatr Blood Cancer. 2021 Apr 12;68(7):e28971. doi: 10.1002/pbc.28971

Figure 3. ATCs armed with hu3F8 BsAbs suppressed GD2(+) xenograft in vivo.

Figure 3.

(A) ATCs armed with increasing arming dose (0.05, 0.5 or 5ug/106 T-cell) of hu3F8-BsAb were used to treat GD2(+) M14 melanoma xenografts in BRG mice. The tumor response was near identical at all three arming dose levels. (n=5 mice/group) (B) Increasing biweekly doses of armed ATCs improved tumor response. (n=5 mice/group). Once: only one time injection, Weekly: weekly injection for total 3 times, Biweekly: biweekly injection for total 6 times.